FLUMIST QUADRIVALENT Rx
Generic Name and Formulations:
Quadrivalent, live attenuated influenza vaccine (virus types A and B); formulation changes annually; susp in intranasal sprayer; contains gelatin, arginine, gentamicin (trace); preservative-free.
Indications for FLUMIST QUADRIVALENT:
Adults and Children:
<2yrs or ≥50yrs: not recommended. Give before start of flu season; each dose is 0.2mL intranasally (as 0.1mL/nostril). 2–8yrs: 1 or 2 doses/season (depends on vaccination history as per annual ACIP recommendation); if 2 doses, give at least 1 month apart. 9–49yrs: 1 dose/season.
Allergy to egg protein, gentamicin, gelatin, or arginine. Life-threatening reaction to previous flu vaccine. Concomitant aspirin in patients 2–17yrs of age (Reye's syndrome).
Use current formulation only. Asthmatics or children <5yrs old with recurrent wheezing: may be at increased risk of wheezing following administration. Guillain-Barre syndrome within 6 weeks of previous flu vaccine. Underlying medical conditions predisposing to flu complications. Immunocompromised. Have epinephrine inj (1:1000) available. Pregnancy (Cat.B). Nursing mothers.
Concomitant vaccines: see full labeling. Do not administer until 48hrs after antiviral therapy cessation. Do not give antivirals within 2 weeks of administration.
Rhinorrhea/nasal congestion, fever, sore throat, decreased appetite, irritability; wheezing.
Single-dose pre-filled nasal spray (0.2mL)—10
Sign Up for Free e-newsletters
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|